OncoGenex Pharmaceuticals, Inc. (OGXI). IG-004 has completed Phase 2 trials in NSCLC, pancreatic cancer, ovarian cancer, colorectal cancer or bladder cancer as well as completed Phase 3 studies in MBC in the US and/or non-US. IGDRASOL recently acquired the IG-004 portfolio asset from OncoGenex. IGDRASOL plans to reexamine the clinical data of IG-004 to map out the best path forward given the benefit of hindsight.
"We intend to leverage our comprehensive domain knowledge of paclitaxel nanoparticle formulations to build a franchise of next generation paclitaxel nanomedicines. I am convinced that our team who played a key role in the development and success of Abraxane® will be able to do it here again," said Vuong Trieu Ph.D., Chief Executive Officer of IGDRASOL.
Also, the acquisition of TOCOSOL® paclitaxel allows IGDRASOL to compare and contrast stable paclitaxel nanoparticles (TOCOSOL® paclitaxel) versus plasma-unstable paclitaxel nanoparticles (Abraxane® and Genexol-PM®). Data mining of these large databases have generated exciting insights into the field of nanomedicine.
Some of the findings are being presented at Nanomedicine 2013, April 11th -12th, Barcelona, Spain. The presentation is entitled: "Non-biologic Nanoparticle Paclitaxel for the Treatment of Cancer" authored by: Vuong Trieu, Catherine Cheng , Larn Hwang, Chao Hsiao , and Kouros Motamed .
Cynviloq™ (or IG-001; a paclitaxel-loaded micellar diblock copolymer) is a next-generation branded paclitaxel formulation currently approved and on the market in several countries as Genexol-PM®.
About Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc. ("STI"; SRNE) is a publicly-traded, development-stage biopharmaceutical company fo
Page: 1 2 3 4 5 Related medicine technology :1
|SOURCE Sorrento Therapeutics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL2
. Sorrento Therapeutics Awarded Third Phase I STTR Grant3
. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering4
. Autoinjectors to 2018 Devices, Therapeutics, Markets, Strategies and Prospect5
. ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"6
. Autoinjectors to 2018 - Devices, Therapeutics, Markets, Strategies and Prospects7
. ADVENTRX Announces Corporate Name Change To "Mast Therapeutics, Inc."; Ticker Symbol Change To "MSTX"8
. Arno Therapeutics, Inc. Appoints Randy Thurman to the Board of Directors9
. Epigenetics Technology Market (Epigenomics, DNA Methylation, Histone Modifications, RNA Interference, Cancer Therapeutics, Personalized Medicine) (2012 - 2017)10
. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option11
. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.